title: [Development of treatment adherence by jellification of itraconazole oral solution].
abstract: There have been some reports on the efficacy and tolerability of itraconazole (ITCZ) as prophylaxis for fungal infection after HSCT, and guidelines recommend itraconazole as a standard drug for prophylaxis of fungal infection in HSCT patients. However, it is not uncommon for patients undergoing HSCT to develop anorexia and taste disturbance. There are some cases where the bitter taste of ITCZ oral solution leads to interruption of administration because the patient refuses to take this medicine. Therefore, we investigated the clinical utility and influence on continuing treatment adherence by jellification of ITCZ. Compared with ITCZ oral solution, jellified ITCZ was extremely easy for most patients to take, and it was suggested that jellified ITCZ can make it easier for patients to continue treatment if they have difficulty with administration because of the bitter taste of ITCZ oral solution. Furthermore, it was confirmed that the plasma concentration of ITCZ was suitable for prophylaxis even with jellified ITCZ. This also suggested that the efficacy of ITCZ would be maintained by using jellified formation. For long-term antifungal therapy in patients with a high risk of fungal infection such as those having HSCT, it is very important for successful prophylaxis to maintain good adherence.
authors.affiliation: Division of Hematology, Department of Medicine, Kawasaki Medical School.
authors.forename: Hideho
authors.initials: H
authors.lastname: Wada
authors.forename: Satoko
authors.initials: S
authors.lastname: Tanabe
authors.forename: Kazuko
authors.initials: K
authors.lastname: Ichikawa
authors.forename: Fuminori
authors.initials: F
authors.lastname: Sano
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Kubo
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Matsuhashi
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Nakanishi
authors.forename: Taizo
authors.initials: T
authors.lastname: Tasaka
authors.forename: Takashi
authors.initials: T
authors.lastname: Sugihara
mesh_terms: D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000097:blood; D004304:Dosage Forms; D004339:Drug Compounding; D005260:Female; D005782:Gels; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D017964:Itraconazole / Q000008:administration & dosage* / Q000097:blood; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000517:prevention & control; D010349:Patient Compliance; D012996:Solutions
chemical_list: D000935:Antifungal Agents; D004304:Dosage Forms; D005782:Gels; D012996:Solutions; D017964:Itraconazole